190 related articles for article (PubMed ID: 21913738)
1. Special considerations with the use of intravenous immunoglobulin in older persons.
Cheng MJ; Christmas C
Drugs Aging; 2011 Sep; 28(9):729-36. PubMed ID: 21913738
[TBL] [Abstract][Full Text] [Related]
2. Intravenous immunoglobulin: adverse effects and safe administration.
Orbach H; Katz U; Sherer Y; Shoenfeld Y
Clin Rev Allergy Immunol; 2005 Dec; 29(3):173-84. PubMed ID: 16391392
[TBL] [Abstract][Full Text] [Related]
3. Safety of intravenous immunoglobulin in the elderly treated for a dysimmune neuromuscular disease.
Lozeron P; Not A; Theaudin M; Denier C; Masnou P; Sarov M; Adam C; Cauquil C; Adams D
Muscle Nerve; 2016 May; 53(5):683-9. PubMed ID: 26467654
[TBL] [Abstract][Full Text] [Related]
4. Surveillance study on the tolerability and safety of Flebogamma
Alsina L; Mohr A; Montañés M; Oliver X; Martín E; Pons J; Drewe E; Papke J; Günther G; Chee R; Gompels M;
Pharmacol Res Perspect; 2017 Oct; 5(5):. PubMed ID: 28971614
[TBL] [Abstract][Full Text] [Related]
5. Predictive factors of first dosage intravenous immunoglobulin-related adverse effects in children.
Kubota J; Hamano SI; Daida A; Hiwatari E; Ikemoto S; Hirata Y; Matsuura R; Hirano D
PLoS One; 2020; 15(1):e0227796. PubMed ID: 31929600
[TBL] [Abstract][Full Text] [Related]
6. Intravenous immunoglobulin-associated acute renal failure: case series and literature review.
Itkin YM; Trujillo TC
Pharmacotherapy; 2005 Jun; 25(6):886-92. PubMed ID: 15927908
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature.
Marie I; Maurey G; Hervé F; Hellot MF; Levesque H
Br J Dermatol; 2006 Oct; 155(4):714-21. PubMed ID: 16965420
[TBL] [Abstract][Full Text] [Related]
8. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: a case-control study.
Moulis G; Sailler L; Sommet A; Lapeyre-Mestre M; Montastruc JL;
Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):314-9. PubMed ID: 21953992
[TBL] [Abstract][Full Text] [Related]
9. Acute renal failure after large doses of intravenous immune globulin.
Haskin JA; Warner DJ; Blank DU
Ann Pharmacother; 1999; 33(7-8):800-3. PubMed ID: 10466908
[TBL] [Abstract][Full Text] [Related]
10. Safety of intravenous immunoglobulin (IVIG) therapy.
Katz U; Achiron A; Sherer Y; Shoenfeld Y
Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
[TBL] [Abstract][Full Text] [Related]
11. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
Gürcan HM; Ahmed AR
Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
[TBL] [Abstract][Full Text] [Related]
12. Venous and arterial thrombosis following administration of intravenous immunoglobulins.
Paran D; Herishanu Y; Elkayam O; Shopin L; Ben-Ami R
Blood Coagul Fibrinolysis; 2005 Jul; 16(5):313-8. PubMed ID: 15970713
[TBL] [Abstract][Full Text] [Related]
13. Evidence-based strategies to reduce intravenous immunoglobulin-induced headaches.
Thornby KA; Henneman A; Brown DA
Ann Pharmacother; 2015 Jun; 49(6):715-26. PubMed ID: 25757469
[TBL] [Abstract][Full Text] [Related]
14. Not all intravenous immunoglobulin preparations are equally well tolerated.
Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
[TBL] [Abstract][Full Text] [Related]
15. [Intravenous immunoglobulins and acute renal failure: mechanism and prevention].
Fakhouri F
Rev Med Interne; 2007 May; 28 Spec No. 1():4-6. PubMed ID: 17768831
[TBL] [Abstract][Full Text] [Related]
16. Severe antibody-mediated rejection following IVIG infusion in a kidney transplant recipient with BK-virus nephropathy.
Mainra R; Xu Q; Chibbar R; Hassan A; Shoker A
Transpl Immunol; 2013 Jun; 28(4):145-7. PubMed ID: 23685054
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with headache in intravenous immunoglobulin treatment for neurological diseases.
Graf J; Ingwersen J; Lepka K; Albrecht P; Hartung HP; Ringelstein M; Aktas O
Acta Neurol Scand; 2019 Oct; 140(4):290-295. PubMed ID: 31269227
[TBL] [Abstract][Full Text] [Related]
18. Acute renal failure and intravenous immune globulin: sucrose nephropathy in disguise?
Perazella MA; Cayco AV
Am J Ther; 1998 Nov; 5(6):399-403. PubMed ID: 10099084
[TBL] [Abstract][Full Text] [Related]
19. Nephrotoxicity of intravenous immunoglobulin.
Levy JB; Pusey CD
QJM; 2000 Nov; 93(11):751-5. PubMed ID: 11077032
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of low-dose intravenous immune globulin (IVIG) treatment for infants and children with immune thrombocytopenic purpura. Low-Dose IVIG Study Group.
Warrier I; Bussel JB; Valdez L; Barbosa J; Beardsley DS
J Pediatr Hematol Oncol; 1997; 19(3):197-201. PubMed ID: 9201140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
